Repository logo
 

Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

In neurodegenerative diseases, microglia switch to an activated state, which results in excessive secretion of pro-inflammatory factors. Our work aims to investigate how this paracrine signaling affects neuronal function. Here, we show that activated microglia mediate non-cell-autonomous inhibition of neuronal autophagy, a degradative pathway critical for the removal of toxic, aggregate-prone proteins accumulating in neurodegenerative diseases. We found that the microglial-derived CCL-3/-4/-5 bind and activate neuronal CCR5, which in turn promotes mTORC1 activation and disrupts autophagy and aggregate-prone protein clearance. CCR5 and its cognate chemokines are upregulated in the brains of pre-manifesting mouse models for Huntington's disease (HD) and tauopathy, suggesting a pathological role of this microglia-neuronal axis in the early phases of these diseases. CCR5 upregulation is self-sustaining, as CCL5-CCR5 autophagy inhibition impairs CCR5 degradation itself. Finally, pharmacological or genetic inhibition of CCR5 rescues mTORC1 hyperactivation and autophagy dysfunction, which ameliorates HD and tau pathologies in mouse models.

Description

Journal Title

Neuron

Conference Name

Journal ISSN

0896-6273
1097-4199

Volume Title

Publisher

Elsevier

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Sponsorship
Wellcome Trust (095317/Z/11/Z)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (860035)
National Institute for Health and Care Research (IS-BRC-1215-20014)
We are grateful to Alzheimer’s Research UK, the UK Dementia Research Institute (funded by the MRC, Alzheimer’s Research UK and the Alzheimer’s Society) (to DCR), The Tau Consortium, an anonymous donation to the Cambridge Centre for Parkinson-Plus, the Wellcome Trust ((095317/Z/11/Z) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860035 (D.C.R., M.R.), and Cambridge Australia Scholarships (to AD) for funding.